Cosmos is a dataset created in collaboration with a community of health systems using Epic and is designed to improve patient care. By combining their data, participating organizations and Epic can make new discoveries and advance medicine. Cosmos also powers tools at the point of care, providing insights to clinicians that are tailored to the patient in front of them.
More about Cosmos →

Cosmos Community

256 Million
Meet a few of our Cosmos community members:
San Francisco Department of Public Health
American University of Beirut Medical Center Beirut, Lebanon  Lebanon
Tampa General Hospital
Penn Medicine
Yale New Haven Health System and Yale University
Hartford HealthCare
Learn more about the Cosmos community →

Cosmos in Action

Cosmos at the Point of Care

The vision for Cosmos has always included empowering providers with data to improve care for their patients. With our recently released and ongoing development of Cosmos-enabled features, providers can use attributes from the patient in front of them to review personalized insights they can use alongside their own expertise and experience to partner with their patient on shared decision-making. Some examples include:

Best Care Choices

To further evidence-based care, Best Care Choices for My Patient shows providers insights into how similar patients responded to the treatments they are considering, right at the point of care. Physicians will be able to explore the collective knowledge from millions of clinical decisions to see treatments and resulting outcomes for patients like the one in front of them.


Very rare conditions and medical mysteries often result in limited evidence for a physician to draw from when determining a course of action or treatment for their patient. Look-Alikes enables providers to connect with other providers across the Cosmos community who might have experience with patients with a similar constellation of symptoms or condition so they can collaborate on care.

Condition-Specific Growth Charts

Standard growth charts often don't account for disease-specific nuances that can influence a child's development. When a chronic condition affects a child’s growth, Cosmos enables growth charts that show clinicians and family members how the child is progressing relative to others with the same disease.

Publications Using Cosmos

Researchers in the Cosmos community have published dozens of papers using Cosmos data. Below are several examples of publications that used Cosmos data as part of their analysis.

Epic Research

While traditional research continues to serve as a primary source of information to inform clinical practice, we identified a need for a new kind of analysis focused on getting good data out quickly to clinicians and decision-makers where it can make a difference. To address this need, we launched Epic Research. Using our dual-team process, Epic Research teams evaluate timely, topical, and relevant questions and make findings available to the public at no-cost at
Proportion of Patients by Weight Change After Stopping Semaglutide

Many Patients Maintain Weight Loss a Year After Stopping Semaglutide and Liraglutide

More than half of patients are able to maintain weight loss achieved while on semaglutide or liraglutide even a year after discontinuing the medication.

Read the full brief on Epic Research →
Fentanyl and Opiate Toxicology Screening Rates

Fentanyl Toxicology Screenings for Overdoses on the Rise

Fentanyl testing rate up to nearly 14% of overdose ED encounters, still lags behind opiate testing.

Read the full brief on Epic Research →
Percentage of Encounters for Strep Throat

Strep Throat Infections Up 30% From 2017 Peak After Pandemic Drop

Despite significant drops in 2020 and low rates in 2021 through the beginning of 2022, strep throat infections exceeded their 2017 peak by 30% in February 2023.

Read the full brief on Epic Research →
Pregnancy and Neonatal Outcomes – Weight Loss Medication Prescriptions in the 90 Days Prior to Pregnancy

Increased Risk of NICU Stays for Babies Born to Mothers Prescribed GLP-1 Medications in the 90 Days Before Pregnancy

Babies born to non-diabetic mothers prescribed glucagon-like peptide-1 receptor agonist (GLP-1) medications in the 90 days before pregnancy are 21% more likely to be admitted to the NICU than babies born to mothers not prescribed weight loss medications.

Read the full brief on Epic Research →
Explore more studies and data insights from Cosmos
on Epic Research →
Copyright © Epic Systems Corporation 2024.
This page is not viewable using Internet Explorer. Please try accessing it with an alternate browser.